[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-acute-lymphoblastic-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-acute-lymphoblastic-leukemia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100621722","weight-gain-in-pediatric-leukemia-survivors-100621722",false,"NCT07374315","Weight Gain in Pediatric Leukemia Survivors","A Family-based Intervention Approach to Address Weight Gain in Pediatric Leukemia Survivors","Patient Eligibility Criteria:\n\n* Must have a diagnosis of ALL (T or B cell).\n* Must be receiving standard of care maintenance chemotherapy or be within 6 months of having concluded maintenance chemotherapy at the time of enrollment.\n* Must be at least 6 years of age and no older than 18 years of age at time of enrollment.\n* Must be able to speak and understand English.\n* Must have a caregiver who is participating in this study.\n* Must be able to perform some level of exercise (e.g., a brisk walk for at least five minutes) as determined by self-report.\n* Must not have severe developmental delay\u002Fintellectual disabilities (such as Trisomy32, severe presentations of autism spectrum disorder) or significant mental illness (such as active suicidal ideation, psychotic symptoms, manic or hypomanic episodes, or severe substance use disorder) that may interfere with ability to participate in modified Family Based Therapy (FBT).\n* Patients 10 and older must have a negative SCOFF screen for disordered eating (Score of 2 or more would disqualify the patient and require discussion with primary team)\n* Must be able to understand and willing to sign an IRB-approved written informed consent document or be able to provide verbal assent along with written consent provided by a legally authorized representative.\n\nCaregiver Eligibility Criteria:\n\n* Self-reported as the primary caregiver of a pediatric patient diagnosed with ALL who is also participating in this study.\n* Must be at least 18 years of age.\n* Must be able to speak and understand English.\n* Must be able to perform some level of exercise (e.g., a brisk walk for at least five minutes) as determined by self-report\n* Must be able to understand willing to sign an Institutional Review Board (IRB)-approved written informed consent document.","ALL","6 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a trial assessing the efficacy of two weight maintenance programs for children with acute lymphoblastic leukemia (ALL) and the patients' caregivers. Patients and their caregivers will be randomized 1:1 to Arm A, a non-intensive educational intervention using National Institute of Health (NIH) Educational Resources (We Can! for children 8-13 and Take Charge of Your Health for teenagers 14-18), or Arm B, a Modified Guided Self-Help Family Intervention for Leukemia patients (mL-GSH). Outcomes will be assessed through activity trackers, obesity biometrics, and nutrition and physical activity assessments.",[26,27,28,29],"Leukemia","Pediatric Acute Lymphoblastic Leukemia","Pediatric Acute Lymphoblastic Leukemia in Remission","Pediatric Obesity",[26,31,32,33,34,35],"Lymphoblastic Leukemia","Weight Management","Late Effects","Health Behaviors","Healthy Habits","NOT_YET_RECRUITING","2026-04-23",{"date":39,"type":40},"2026-04-28","ACTUAL",{"date":42,"type":20},"2026-05-31",{"date":44,"type":20},"2029-02-28",{"name":46,"class":47},"Washington University School of Medicine","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100623976","integrative-multi-omics-and-functional-platform-for-the-complete-diagnostic-characterization-of-tumors-the-italian-tumor-chemogenomic-profiler-it-tcp-100623976","NCT07403630","INTEGRATIVE \"MULTI-OMICS\" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)","IT-TCP POS","Inclusion criteria:\n\n* Patients aged one year and over who are referred to the centres involved in the protocol (Azienda Ospedaliero-Universitaria di Parma, University of Parma, University of Perugia and Azienda Ospedali Riuniti Villa Sofia-Cervello of Palermo).\n* Patients with an established diagnosis of haematological or solid organ malignancy, including haematological or solid malignancies characteristic of the paediatric age group.\n* Patients diagnosed with relapsed, refractory and\u002For metastatic haematological or solid malignancy. Patients may be enrolled regardless of the extent and type of previous therapy. Patients may also be enrolled if they are undergoing active treatment at the time of evaluation.\n* Patients must have the capacity to understand the investigative nature of the study and provide informed consent in writing. For patients under the age of 12 years, consent will be provided by the parent\u002Flegal guardian according to international guidelines. For patients aged 12 to 17 years, consent will be provided by the patient and the parent\u002Flegal guardian according to the mature minor principle.\n\nExclusion criteria:\n\n* Patients younger than 1 year old\n* Patients with active, uncontrolled infections","1 Year",{"count":58,"type":20},300,[23],"This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.",[62,63,64,65,66,67,68,69,27,70,71,72],"Acute Leukemia","Multiple Myeloma","Squamous Cell Carcinoma","Pleural Mesothelioma","Pancreatic Cancer","Bladder Cancer","Ovarian Cancer","Melanoma","Chronic Leukemia","Myeloproliferative Disorders","Myelodysplastic Disorders","RECRUITING","2026-02-13",{"date":76,"type":40},"2026-02-17",{"date":78,"type":40},"2023-05-31",{"date":80,"type":20},"2028-02-12",{"name":82,"class":47},"Azienda Ospedaliero-Universitaria di Parma",2,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100530225","phase-2-treatment-of-newly-diagnosed-high-risk-pediatric-acute-lymphoblastic-leukemia-100530225","NCT06184009","Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia","Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia-prospective, Nationwide, Multi-center Study","HR ALL","\\\u003CInclusion Criteria\\>\n\n* Age: 1year\\~19years of age at diagnosis\n* Patients who are newly diagnosed Pre-B ALL and meet one of the following criteria\n\n  * High-risk group according to the National Cancer Institute (NCI)\u002FRome: Age greater than or equal to 10 years and less than 19 years at diagnosis, or white blood cell count greater than or equal to 50 x 10\\^9\u002FL at diagnosis\n  * If extra-bone marrow lesions are identified at the time of diagnosis, Central nervous system involvement (CNS3) or testicular involvement\n  * High-risk gene variants:\n\nKMT2A rearrangement intrachromosomal amplification of chromosome 21 (iAMP21)\n\n● If subjects are under the age of 10 at the time of diagnosis and took steroids for more than 24 hours within two weeks before the diagnosis, the risk group will be determined by the presence of a whole blood test within three days before starting steroids. If a whole blood test is performed within three days before beginning steroids, the risk group will be assessed based on the white blood cell count in the test. If there is no whole blood test before starting steroids, subjects are classified as a high-risk group. If subjects are ten or older at diagnosis, pre-diagnosis steroid treatment will not affect the risk classification.\n\n* Newly diagnosed T cell ALL\n\n\\\u003CExclusion Criteria\\>\n\n* Patients with Burkitt leukemia\u002Flymphoma or mature B-cell leukemia\n* Patients with Down syndrome\n* potential of pregnancy or during pregnancy (patients of childbearing age need adequate contraception for the duration of the trial)\n* Patients who have already received steroid treatment for newly diagnosed ALL specified in the above selection criteria or chemotherapies more than one intrathecal cytarabine treatment\n* Participating in an interventional clinical trial other than this research","19 Years",{"count":94,"type":20},370,[96],"PHASE2","* Clinical and genetic factors consistent with High risk : Induction → Consolidation\n\n  1. BM MRD \\< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance\n  2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance\n  3. BM MRD ≥ 0.01% after Consolidation\n\n  \u003C!-- -->\n\n  1. T cell ALL : Change to very high risk regimen\n  2. Pre-B ALL : IM #1 → Intensification\n\n     1. BM MRD \\< 0.01% after IM #1 : DI #1 → IM #2 → DI #2 → Maintenance\n     2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen\n\n        * Difference in the number of \\'interim maintenance(IM)\\' and \\'delayed intensification(DI)\\' is important for chemotherapies based on MRD.",[27],[90,100],"NGS-MRD","2025-06-04",{"date":103,"type":40},"2025-06-08",{"date":105,"type":40},"2024-08-10",{"date":107,"type":20},"2030-12-31",{"name":109,"class":47},"Jae Wook Lee",7]